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ercutaneous Aortic Valve Replacement
ill Become a Common Treatment for
ortic Valve Disease
ohn G. Webb, MD
ancouver, British Columbia, Canada
ercutaneous valve replacement is developing into an effective and reproducible therapy for aortic
alve stenosis. Initial experience suggests that outcomes compare favorably with conventional valve
urgery in selected patients with comorbidities, such as advanced age. Caution is prudent, however, in
he future a more mature procedure might represent a viable alternative for a much broader range of
atients. (J Am Coll Cardiol Intv 2008;1:122–6) © 2008 by the American College of Cardiology
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phe advent of percutaneous aortic valve replace-
ent (PAVR) can be considered to have begun in
992 when Andersen et al. (1) demonstrated the
easibility of intravascular implantation of a
atheter-mounted valved stent in an animal model.
everal groups pursued the goal of aortic valve
mplantation, but it was not until 10 years later that
he first successful percutaneous valve implantation
n a patient with aortic stenosis was reported by
ribier et al. (2). Despite initial stumbles, PAVR is
ecoming a clinical reality, with over 500 proce-
ures performed to date and commercial release in
any countries.
See page 127
hy Percutaneous Valve Implantation?
evere aortic stenosis is common and, when symp-
omatic, is associated with a predictably high mor-
ality (3,4). Aortic valve surgery can be performed
t very low risk with marked benefit in terms of
urvival and symptoms (4). However, the risk of
ortality and morbidity with sternotomy, cardio-
rom the Division of Cardiology, St. Paul’s Hospital, University of
ritish Columbia, Vancouver, Canada. Dr. Webb is a consultant to
dwards Lifesciences, Inc., and a McLeod Professor of Heart Valve
ntervention.e
anuscript received October 9, 2007; revised manuscript received
ovember 1, 2007, accepted November 15, 2007.ulmonary bypass, aortotomy, and valve replace-
ent is not always low, particularly in the elderly
atient with comorbidities (4–6). Despite the
otential benefit of valve replacement, many pa-
ients with aortic stenosis are not offered or do not
ccept surgical therapy (3,7).
ranscatheter Valves
he 2 most widely evaluated catheter implantable
alves, the balloon-expandable Edwards SAPIEN
alve (successor to the Cribier-Edwards valve;
dwards Lifesciences, Irvine, California) and the
elf-expanding CoreValve device (CoreValve Inc.,
rvine, California), are shown in Figure 1. As the
rocedure has evolved, standard off-the-shelf bal-
oon catheters have been replaced by more complex
ntegrated valve and valve delivery catheter sys-
ems. Whereas first-generation delivery systems
ere large, requiring 24-F sheaths (external diam-
ter 9 mm), newer systems are being progressively
educed in profile, moving toward the likely limits
f current technology at around 16- to 20-F.
ultiple other valves and delivery systems with
otential advantages in terms of the ability to
eliver, deploy, or reposition the prosthesis are
nder development or in early clinical evaluation
8,9). It will be important to assure that implant
erformance is not compromised in the quest for
ase of implantation.
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123he Procedure
he PAVR is typically performed in a cardiac catheteriza-
ion laboratory or hybrid operating room. General anesthe-
ia is optional. Femoral artery access and hemostasis might
equire cutdown but is increasingly accomplished with
ercutaneous closure (Fig. 2). Conventional balloon valvu-
oplasty is initially performed. The valved stent is typically
ntroduced into a femoral sheath and passed through the
orta. Positioning of the prosthesis within the native valve is
onfirmed with fluoroscopy, aortography, and often trans-
sophageal echocardiography. Burst pacing might be used
o transiently reduce transvalvular flow during deployment
f balloon-expandable valves. The valved stent is expanded
ithin the native aortic valve, displacing and excluding the
iseased leaflets and substituting a new functional valve in
lace of the old. Discharge occurs as early as day 2, although
edian discharge might average 5 days as a consequence of
elayed mobilization and disposition of elderly patients (10).
ransapical Procedure
discussion of percutaneous valve implantation would not
e complete without acknowledging the open chest equiv-
lent, which allows extension of the “transcatheter” tech-
ology to patients with vascular disease. This approach uses
mini-thoracotomy and needle puncture of the apical left
entricle without cardiopulmonary bypass (11,12). Re-
orted experience is favorable but limited (13,14), al-
hough as of late 2007 approximately 200 transapical
alve implantations have been performed worldwide.
arly Outcomes
nitial procedures were performed with a transvenous tech-
ique with puncture of the femoral vein and inter-atrial
eptum allowing antegrade access to the left heart and aortic
Figure 1. Transcatheter Valves
(A) The balloon-expandable Edwards SAPIEN valve incorporates a stainless ste
CoreValve device incorporates a nitinol (nickel titanium) alloy stent with leaﬂets andalve (15,16). In a report of the initial 36, primarily
ransvenous, patients from France, valve implantation was
uccessful in 75% (17). Although problematic, this early
ransvenous experience did document the feasibility of the
rocedure and the potential for durable benefit.
Subsequently we described a transarterial procedure using
emoral arterial access, which seemed more reproducible
nd has supplanted the earlier transvenous procedure (18).
nitial transarterial experience in “high-risk” or “inoperable”
atients was favorable, with successful implantation increas-
ng from 76% to 96% with experience (10). Intra-procedural
ortality was low at 2%. Mortality at 30 days after the
rocedure was 12%, comparing favorably to a logistic
uroSCORE (European System for Cardiac Operative
isk Evaluation) (19) estimate of 28% in this high-risk
roup (Fig. 3). As the Vancouver transcatheter experience
xceeds 150 patients, transarterial success rates continue to
mprove and 30-day mortality has fallen well into the single
igits in high-risk patients (20). As of late 2007, approxi-
ately 300 PAVR procedures have been performed with
alloon expandable valves. Early, as yet unpublished anal-
sis of this global experience, including the multicenter
EVIVE and REVIVE-II (21) trials, confirms similar
utcomes.
Experience with the self-
xpanding CoreValve device
emonstrates similar trends in
utcomes. Grube et al. (22) re-
orted a single-center, 25-patient
xperience in which valve implan-
ation was successful in 84% of
atients with an in-hospital mortality of 20% in a high-risk
roup. A later multicenter report described 86 cases using
ewer lower profile devices with valve implantation successful
n 88% and a 30-day mortality falling to 12% (logistic Euro-
CORE 22%) (23). As of late 2007, approximately 300
t, bovine pericardial leaﬂets, and a fabric sealing cuff. (B) The self-expanding
Abbreviations
and Acronyms
EuroSCORE  European
System for Cardiac Operative
Risk Evaluation
PAVR  percutaneous aortic
valve replacementel sten
a sealing cuff constructed of porcine pericardial tissue.
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124oreValve procedures have been performed. As yet unpub-
ished, global analysis of 175 procedures using the newer
eneration devices demonstrate procedural success in 92% with
 30-day mortality of 15% (logistic EuroSCORE 24%).
alve Function
n vitro and clinical evaluations of currently available trans-
atheter valves demonstrate excellent valve function (Fig. 4).
rifice areas are typically larger than comparable surgical
Figure 2. Percutaneous Access and Closure
(Left) Needle puncture of the common femoral artery was followed by placem
eter (9 mm external diameter) sheath. After valve implantation, a knot pusher
(Right) Hemostasis was achieved immediately after sheath removal without th
anticipated to make percutaneous closure more routine.
Figure 3. Outcomes in the Initial Vancouver Transarterial Percutaneous
Balloon Expandable Aortic Valve Replacement First-in-Man Series
Success rates and mortality improved in the second half of the experience
(10). Logistic EuroSCORE (19) is an estimate of 30-day mortality after sur-
gery but might overestimate mortality in some high-risk patients.rostheses, owing to the absence of a bulky sewing ring and
he ability to implant oversized prostheses after balloon
ilation. Echocardiographic evaluation of both currently
vailable valves typically documents gradients of under 10
m Hg and effective orifice areas of over 1.5 cm2 (10).
Initial experience with transcatheter valves suggested that
aravalvular regurgitation was often severe (2,17,24). With
arious modifications of the procedure, such severe leaks are
nfrequent. Although paravalvular regurgitation remains
biquitous, such leaks are generally mild (10,25) and hemo-
ysis has not been observed (26). For the most part clinical
f percutaneous arterial sutures before insertion of a large 24-F internal diam-
d to advance the sutures knots through the subcutaneous tissues to artery.
d for surgical exposure of the artery. Future reduction in sheath diameter is
Figure 4. Transaortic Gradients
Left ventricular (LV) to aortic gradients before and after percutaneous aor-ent o
is use
e neetic valve replacement. FA  femoral artery.
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125onsequences are not apparent, although further improve-
ents are certainly desirable (10,27).
In vitro valve testing predicts durability comparable to
hat seen with surgical bioprostheses. In vivo valve failure
ust be expected eventually, although this has not been
eported with the currently available valves. Admittedly,
ollow-up of reasonable numbers of implants is limited to 2
ears (10,20,23), with only a few patients followed out to 4
ears. Importantly, early experience with implantation of
ranscatheter valves within failed surgically implanted bio-
rostheses sets the scene for a “valve in valve” procedure that
ight be, at least in a limited sense, repeatable when
ercutaneous valves do fail (28 –30).
omplications of Percutaneous Valves
f great concern is the possibility of arterial dissection or
erforation while manipulating very large catheters through
he vasculature (10,31). As with any procedure in a patient
ith aortic stenosis, myocardial ischemia and cardiogenic
hock might occur (31). A unique concern with transcath-
ter valves is the possibility of coronary obstruction by the
rosthetic or native valve, although this seems infrequent
18,23). As with aortic valve surgery, PAVR is associated
ith a finite risk of atrio-ventricular block and pacemaker
ependence (32). Reported rates of stroke with transcathe-
er valve implantation vary from 3% to as high as 9% in 1
eport (10,14,18,22,23,33). Hopefully these risks will di-
inish as the procedure improves and is applied to patients
ith fewer comorbidities.
ate Outcomes
cute and sustained improvements in left ventricular sys-
olic function, functional mitral insufficiency, and functional
lass have been demonstrated after PAVR (10,20,23,34). In
ur initial experience left ventricular ejection fraction in-
reased from 53% to 57% and mitral insufficiency from
rade 2 to grade 1 within days, and this improvement was
ustained at 1 year (10). In the high-risk candidates cur-
ently undergoing these procedures, 1-year survival seems
imited by comorbidities rather than valvular or coronary
isease (10,14).
hich Patients Are Candidates?
n our experience most patients with aortic stenosis are,
rom a purely technical standpoint, candidates for PAVR.
evertheless, conventional valve surgery remains the proven
herapy of choice for the majority of patients with symp-
omatic aortic stenosis, at this time. Percutaneous aortic
alve replacement should only be considered in patients in
hom comorbidities greatly increase the risk of conven-
ional surgery but have a lesser impact on the risk of aranscatheter procedure. To date PAVR has been performed
nly in patients at high surgical risk. Objective estimates of
urgical mortality have been used to help define “high-risk”
35). A logistic EuroSCORE 20 or Society of Thoracic
urgeons (STS) score 10 might be of some value in
ecision-making (19).
The major specific contraindication to PAVR via the
emoral artery is the presence of severe ilio-femoral stenosis
10). Some patients might have an aortic annulus that is too
mall or too large (current prostheses are suitable for an
chocardiographic annulus diameter between 18 and 26
m) (25). Others might have an unusually bulky valve at
isk of obstructing a coronary ostium (18). Mitral insuffi-
iency and non-revascularized coronary disease are not
ecessarily contraindications; both are often well-tolerated
n elderly patients, once aortic stenosis is relieved (10).
owever severe left ventricular dysfunction, severe mitral
alve disease or nonrevascularized coronary disease can
redispose to hemodynamic instability during PAVR.
onclusions
ercutaneous aortic valve replacement offers the potential
or significant benefit but is not without risk. Optimal
utcomes will require cautious application, technological
nd procedural improvements, formal training, centers of
xpertise, further trials, and ongoing surveillance. Currently
his procedure can be considered for symptomatic patients
ho are poor candidates for conventional surgery. A more
ature procedure might soon offer a viable alternative to a
uch broader range of patients.
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